AnaSpec Introduces Speedy 28-Day Antibody Service

Online, August 11, 2010 (Newswire.com) - Contact: Albert Olson Hong
Tel: 510-791-9560 x 243
Email: [email protected]

AnaSpec Introduces Speedy 28-Day Antibody Service

Fremont, CA

AnaSpec introduces the Speedy 28-day custom polyclonal antibody service. Leveraging proven technology from Eurogentec, AnaSpec's parent company, this protocol uses a proprietary mixture of Freund's free immuno-stimulatory compounds. The first bleed, obtained at the accelerated rate of Day 21 after the first immunization of a peptide antigen, is guaranteed to have a titer of at least 1/20,000 for one of the immunized rabbits.

Pricing of this polyclonal antibody package includes:
· Peptide design from protein of interest
· Peptide synthesis (>90%, 15 aa, 3-4 weeks)
· Conjugation to carrier protein (KLH, BSA or OVA)
· Choice of two New Zealand rabbits in SPF or non-SPF environment
· 28-day immunization protocol (not including peptide synthesis)
· ELISA at Day 28
· Antigens include single peptide or two peptides or customer-supplied protein (titer guarantee does not apply to customer-supplied protein)

About AnaSpec

AnaSpec is a leading provider of integrated proteomics solutions to the world's largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.

AnaSpec recently joined forces with Eurogentec to provide an even broader spectrum of products and services to serve the worldwide life science community.

For more information visit www.anaspec.com

About Eurogentec

Eurogentec is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec's Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.

Eurogentec is a privately held company headquartered in Liège, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.

For more information visit www.eurogentec.com

###